Evento
Pharmacological Inhibition Of P300 Displays Antimetastatic Activity In Triple Negative Breast Cancer
Gallardo, Guillermina Ana
; Ferronato, María Julia
; Alonso, Eliana Noelia
; Colo, Georgina Pamela
; Clemente, Valentina
; Facchinetti, Maria Marta
; Curino, Alejandro Carlos
; Fermento, María Eugenia








Tipo del evento:
Congreso
Nombre del evento:
LVI Reunión Anual de la Asociación Argentina de Farmacología Experimental
Fecha del evento:
23/10/2024
Institución Organizadora:
Asociación Argentina de Farmacología Experimental;
Título del Libro:
LVI Reunión Anual De La Asociación Argentina De Farmacología Experimental
Título de la revista:
ABSTRACT BOOK AAFE 2024
Editorial:
Asociación Argentina de Farmacología Experimental
ISBN:
978-631-90806-0-5
Idioma:
Inglés
Clasificación temática:
Resumen
Triple negative breast cancer (TNBC) is a molecular subtype of BC that is known for having a poor prognosis and limited therapeutic options. Therefore, it is necessary to investigate potential therapeutic targets for this pathology. A relationship between p300 and cancer has been demonstrated; but its role remains unclear, as it has been documented both as a tumor suppressor and an oncoprotein. Previously, we have shown that pharmacological inhibition of p300 has an antitumoral effect in the hormone-independent breast cancer cell line, LM3 and its syngeneic murine model. Further, we observed that pharmacological inhibition of p300 reduces migration, invasion and adhesion processes in TNBC MDA-MB-231 cells, indicating the need to further investigate the involved molecules. It is known that E-cadherin and β-catenin are key proteins in adhesion processes between epithelial cells and a decrease in their membrane expression is linked to a pro-tumor phenotype. Therefore, we proposed to investigate the effect of pharmacological inhibition of p300 on stress fiber formation and E- cadherin and β-catenin expression in TNBC cell line and its xenograft model. MDA-MB-231 cells were treated with VV59 (inhibitor of p300 histone acetyltransferase activity) or its vehicle. We detected an increase in E-cadherin and in membrane β-catenin expression in cells treated with VV59 compared to vehicle (immunofluorescence, p˂0.01). In addition, cells stained with fluorescently labeled phalloidin revealed a decrease in stress fibers in cells treated with VV59 compared to vehicle (p˂0.01). In a murine xenograft model of MDA-MB-231 we detected an increase in E-cadherin and in membrane β-catenin expression (immunohistochemistry, p<0.01) in the tumors of animals injected with VV59 compared to the control group. Also, in such a group of mice, we found a significant reduction in the number of lung metastases with respect to the control group (p<0.05). These results suggest a prometastatic role of p300 in TNBC.
Palabras clave:
P300
,
TRIPLE NEGATIVE BREAST CANCER
,
METASTASES
Archivos asociados
Licencia
Identificadores
Colecciones
Eventos(INIBIBB)
Eventos de INST.DE INVEST.BIOQUIMICAS BAHIA BLANCA (I)
Eventos de INST.DE INVEST.BIOQUIMICAS BAHIA BLANCA (I)
Citación
Pharmacological Inhibition Of P300 Displays Antimetastatic Activity In Triple Negative Breast Cancer; LVI Reunión Anual de la Asociación Argentina de Farmacología Experimental; Bahia Blanca; Argentina; 2024; 87-87
Compartir